NEW YORK, NY--(Marketwired - Apr 3, 2013) - Fannie Mae (OTCQB: FNMA) released their most recent 8-K filing yesterday that sent the securities to its highest PPS in nearly five years. The stock hit a high of $1.00 per share briefly and finished the trading session at $0.90 up 12.92% on news of $17.2 B in profits for 2012 with a record $7.6 B in the 4th quarter, FNMA paid $11.6 B in dividends to the U.S. Treasury, and reached a resolution agreement with Bank of America. What has been missed in the excitement is the projected goal set by FNMA to be accomplished in the 1st quarter of 2013. To read the full report about this goal and the projected dividend payoff to the U.S. Treasury follow the link provided: http://bit.ly/FPPREPORT-FNMA
Zynga Inc. (NASDAQ: ZNGA) is up $0.83 per share from $2.24, since we last issued a report on Oct. 29, 2012. That is a gain of over 37% with a current stock price of $3.07 at the close of trading April, 2nd, 2013. We are now offering more insight on this very competitive and fickle industry. To read about new company information recently released and industry competitors follow the link provided: http://bit.ly/FPPREPORT-ZNGA
e.Digital Corp. (OTCQB: EDIG) traded over 3 times its daily 3 month average on April 2nd, 2013 with a news release that their law firm Handal & Associates added 5 more lawsuits to bring the total to 21. The cases target smartphone manufacturers and resellers including RIM, Motorola, Apple, Huawei and ZTE. The complaints allege that products made by the Defendants infringe e.Digital's patents covering the use of flash memory technologies. The stock ended the day's trading session up 2.5% at $0.1845 which is lower than expected. To find out why this recent news did not gain the traction shareholders were looking for read the full report at: http://bit.ly/FPPREPORT-EDIG
Inovio Pharmaceuticals Inc. (NYSE: INO) had gross revenues in 2012 of approximately 4.1M vs. 2011 gross revenues of 9.8M however, Inovio's 2012 revenues are almost double that of 2008. We see some promising potential new drugs in their development portfolio that could add substantial revenue to the bottom line and kick start a rebound in these securities. In the following report, there is a description of these along with a detailed chart on each treatments progress in the FDA approval process: http://bit.ly/FPPREPORT-INO
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.